StockNews.com Downgrades Emergent BioSolutions (NYSE:EBS) to Hold

Emergent BioSolutions (NYSE:EBS) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Saturday.

A number of other analysts have also recently issued reports on EBS. Rodman & Renshaw reissued a “buy” rating and issued a $16.00 target price on shares of Emergent BioSolutions in a research report on Friday, September 13th. Benchmark increased their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th.

Emergent BioSolutions Stock Performance

NYSE EBS opened at $8.27 on Friday. The company has a fifty day moving average of $9.23 and a two-hundred day moving average of $8.84. The company has a market capitalization of $448.10 million, a PE ratio of -2.02 and a beta of 1.59. Emergent BioSolutions has a 1 year low of $1.42 and a 1 year high of $15.10. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47.

Institutional Investors Weigh In On Emergent BioSolutions

A number of institutional investors and hedge funds have recently made changes to their positions in the business. State Street Corp grew its holdings in shares of Emergent BioSolutions by 864.7% during the third quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock worth $15,960,000 after buying an additional 1,713,200 shares during the last quarter. Oak Hill Advisors LP acquired a new stake in Emergent BioSolutions during the 3rd quarter worth approximately $9,296,000. Millennium Management LLC grew its stake in shares of Emergent BioSolutions by 5.8% in the 2nd quarter. Millennium Management LLC now owns 946,302 shares of the biopharmaceutical company’s stock valued at $6,454,000 after purchasing an additional 52,144 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Emergent BioSolutions by 240.9% in the 2nd quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock valued at $6,015,000 after purchasing an additional 623,201 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Emergent BioSolutions by 74.5% in the third quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock valued at $6,192,000 after purchasing an additional 316,700 shares during the period. 78.40% of the stock is owned by hedge funds and other institutional investors.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.